Laurus Labs Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Laurus Labs Ltd is ₹ 1164 as of 05 May 15:30 . The P/E Ratio of Laurus Labs Ltd changed from 19.8 on March 2021 to 92.4 on March 2025 . This represents a CAGR of 36.08% over 5 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Laurus Labs Ltd changed from ₹ 19427 crore on March 2021 to ₹ 33099 crore on March 2025 . This represents a CAGR of 11.24% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Laurus Labs Ltd for the Mar '26 is ₹ 1823 crore as compare to the Dec '25 revenue of ₹ 1784 crore. This represent the growth of 2.2% The revenue of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 39.95 crore. This represent the decline of -100% The ebitda of Laurus Labs Ltd for the Mar '26 is ₹ 523.91 crore as compare to the Dec '25 ebitda of ₹ 485.97 crore. This represent the growth of 7.81% The ebitda of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 27.95 crore. This represent the decline of -100% The net profit of Laurus Labs Ltd changed from ₹ 90.61 crore to ₹ 281.91 crore over 8 quarters. This represents a CAGR of 76.39% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Laurus Labs Ltd changed from 11.22 % on March 2021 to 17.01 % on March 2025 . This represents a CAGR of 8.68% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Laurus Labs Ltd

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company.
The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007.
Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007.
Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007.
Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Laurus Labs Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Laurus Labs Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Laurus Labs Ltd is 62,974 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,335 Cr

What are the key factors driving the stock performance of Laurus Labs Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Laurus Labs Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Laurus Labs Ltd and Shukra Pharmaceuticals Ltd?

As of May 5, 2026, the Laurus Labs Ltd stock price is INR ₹1166.5. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹30.5.

How do dividend payouts of Laurus Labs Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Laurus Labs Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.